Drug Trial Radar · NCT05789745
A Study to Evaluate Plasma Gelsolin in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 14, 2023
Primary completion
May 24, 2023
Study completion May 24, 2023
Sponsor
- Lead sponsor
- BioAegis Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study BTI-101 is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation, parallel design study to evaluate the safety, tolerability, and pharmacokinetics of IV rhu-pGSN or saline placebo administered as 5 doses each of 6, 12, 18, or 24 mg/kg of body weight. Each of 4 dosing cohorts will include 8 subjects randomized 3:1 rhu-pGSN:placebo (6 rhu-pGSN subjects:2 placebo subjects). Subjects will be healthy adult volunteers 18-55 years of age.
Conditions
- Volunteers
- Healthy
Interventions
Recombinant human plasma gelsolinDrug
intravenous administration of either 6, 12, 18, or 24 mg/kg at time 0, 12, 36, 60 and 84 hours
placeboOther
intravenous administration of saline control at time 0, 12, 36, 60 and 84 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: 28 days
- Serious Adverse EventsTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.